SUMMARY
Monocytes serve as a central defense system against infection and injury but can also promote pathological inflammatory responses. Considering the evidence that monocytes exist in at least two subsets committed to divergent functions, we investigated whether distinct factors regulate the balance between monocyte subset responses in vivo. We identified a microRNA (miRNA), miR-146a, which is differentially regulated both in mouse hi / Ly-6C lo ) and human (CD14 hi /CD14 lo CD16 + ) monocyte subsets. The single miRNA controlled the amplitude of the Ly-6C hi monocyte response during inflammatory challenge whereas it did not affect Ly-6C lo cells. miR-146a-mediated regulation was cell-intrinsic and depended on Relb, a member of the noncanonical NF-kB/Rel family, which we identified as a direct miR-146a target. These observations not only provide mechanistic insights into the molecular events that regulate responses mediated by committed monocyte precursor populations but also identify targets for manipulating hi monocyte responses while sparing Ly-6C lo monocyte activity.
INTRODUCTION
Monocytes are the circulating precursors of several types of macrophages and dendritic cells (Geissmann et al., 2010) . They confer protection of injured or infected tissue but also propagate chronic diseases (Auffray et al., 2009; Qian and Pollard, 2010; Shi and Pamer, 2011) . At least two CD11b + CD115 + monocyte populations exist in mice: 1), Ly-6C hi (Gr-1 + CCR2 + CX3CR1 lo ) cells respond to proinflammatory cues such as CCL2 (or MCP-1), migrate to inflamed sites and draining lymph nodes, and can differentiate into antigen-presenting dendritic cells (Cheong et al., 2010) and orchestrate inflammatory functions Tacke et al., 2007) ; and 2), Ly-6C lo (Gr-1 -CCR2 -CX3CR1 hi ) cells patrol the resting endothelium (Auffray et al., 2007) , can be recruited to tissue after the onset of inflammation, and participate in granulation tissue formation (Nahrendorf et al., 2007) . hi monocytes recirculate into the bone marrow where they can convert into Ly-6C lo monocytes (Varol et al., 2007) . Monocyte heterogeneity is conserved at least in part in mice and humans: mouse Ly-6C hi monocytes share phenotypic and functional features with human CD14 hi cells, whereas mouse Ly-6C lo monocytes resemble human CD14 lo CD16 + cells (Cros et al., 2010) . Infection (Shi and Pamer, 2011) , injury (Nahrendorf et al., 2007) , atherosclerosis Tacke et al., 2007) , cancer (Movahedi et al., 2010) , and other pathophysiological conditions alter monocyte subset ratios. Changes of ratios can occur rapidly (e.g., hours after pathogenic infection), be long lasting (e.g., in chronic inflammatory disorders), and typically result in the selective amplification of proinflammatory Ly-6C hi cells. Human studies have underscored the relevance of studying monocyte subsets because an imbalance in their relative proportion is linked to several diseases (Ziegler-Heitbrock, 2007) . The factors that regulate the balance between monocyte subset responses are largely unknown. The identification of such factors is potentially useful as it may offer new vantage points for tailoring immune responses to a desired phenotype.
RESULTS

Mir-146a Is a Candidate Regulator of Monocyte Functional Heterogeneity
MicroRNAs (miRNAs) regulate target genes at the posttranscriptional level and can control distinct functional properties in cell types that are closely related ontogenically. miRNAs are known to regulate the development and function of various immune cell types (O'Connell et al., 2010) but have to date not been investigated in the context of monocyte heterogeneity. Here we compared the expression levels of 380 miRNAs in sorted monocyte subsets ( Figure S1A ) and defined significant genes as those with at least 2-fold differential expression and a p < 0.05 (Student's t test). The approach identified nine miRNAs, which were highly expressed either in Ly-6C
hi (miR-20b, -135a, -424, -702) or in Ly-6C lo monocytes (miR-146a, -150, -155, -342, -29b ) ( Figure 1A ). Independent assays indicated $2 orders of magnitude higher expression of miR-146a in Ly-6C lo monocytes when compared to hematopoietic stem cells (HSC), granulocyte/macrophage progenitors (GMP), macrophage/dendritic cell progenitors (MDP), and Ly-6C hi monocytes in steady-state ( Figure 1B ).
Thus, monocytes express miR-146a only at a late maturation stage and selectively in the Ly-6C lo subset. Steady-state dendritic cell populations expressed miR-146a at intermediate levels ( Figure 1B ). miRNAs and their respective target genes are often mutually exclusively expressed in a given tissue (Farh et al., 2005) . In keeping with previous observations that miR-146a suppresses NF-kB-dependent inflammatory pathways (Taganov et al., 2006) , we confirmed with two independent genome-wide profiling methods that blood miR-146a lo Ly-6C hi monocytes showed increased inflammatory signatures (Swirski et al., 2009 ) and expressed components of the NF-kB signaling cascade at higher levels than their miR-146a hi Ly-6C lo counterparts ( Figures 1C and S1B ). Also, splenic and blood miR-146a lo Ly-6C hi monocytes stimulated with lipopolysaccharide (LPS) produced more TNFa, IL-6, and IL-1b inflammatory cytokines than miR-146a hi Ly-6C lo cells ( Figures 1D and S1C ).
The elevated miR-146a expression in Ly-6C lo cells and the inflammatory profile of Ly-6C hi cells reported above were likely not due to a premature activation artifact induced by the isolation procedure because IkBa protein levels were similar in both monocyte subsets ex vivo ( Figure S1D ) and NF-kB subunit p65 only became detectable in the nucleus of Ly-6C hi cells upon in vitro challenge ( Figure 1E ). The cause for constitutive (NF-kB (D) Quantification of TNFa, IL-6, IL-1b and IL-10 production by splenic monocytes 8 hr after LPS challenge (n = 3-4). (E) p65 immunofluorescence staining in sorted monocyte subsets. Ly-6C hi monocytes stimulated for 30 0 with TNFa prior to fixation served as a positive control for effective nuclear translocation. Scale bar represents 10 mm.
(F) Time-course analysis of miR-146a levels after LPS challenge. Expression is relative to Ly-6C hi monocytes at time 0 hr (n = 2-). Data are presented as mean ± SEM (*p < 0.05, **p < 0.01, ***p < 0.001, Student's t test). See also Figure S1 .
-independent) miR-146a expression in Ly-6C lo cells will require additional investigation.
Differential Mir-146a Expression in Monocytes in Steady State and Inflammation
We addressed the regulation of miR-146a expression in monocyte subsets upon ex vivo challenge with either LPS, heat killed Listeria monocytogenes (HKLM) or TNFa. miR-146a was induced only in Ly-6C hi monocytes, in response to all stimuli, and reached levels matching those in Ly-6C lo cells ( Figure S1E ). In vivo LPS challenge studies confirmed the in vitro findings (Figure S1F) . miR-146a expression in Ly-6C hi cells increased within 4 hr after LPS challenge and reached levels equivalent to those found in Ly-6C lo cells after 16 hr ( Figure 1F Figure S1G ).
Mir-146a Controls Monocyte Subset Ratios during Inflammatory Reactions
To investigate the role of miR-146a in monocytes in vivo, we generated mice in which miR-146a expression was either upor downregulated experimentally. To constitutively overexpress miR-146a we reconstituted mice with HSC transduced to coexpress EGFP and miR-146a ( Figures S2A and S2B ). miR-146a overexpression did not alter monocyte numbers or subset ratios in steady state ( Figure S2C ); however, upon Listeria monocytogenes (Lm) infection (Shi and Pamer, 2011) , it prevented the unfolding of a full-fledged TNFa-producing Ly-6C hi monocyte response (Figures 2A and 2B ).
To suppress miR-146a expression in vivo we used two independent approaches. The first one involved systemic delivery of anti-miRNA locked nucleic acid (LNA) formulations (Figures S2D and S2E) . LNA treatment did not alter monocyte subset ratios in steady state ( Figure S2F ) but it increased the number of TNFa-producing Ly-6C hi monocytes at Lm infected sites ( Figures 2C and 2D ). The second approach to suppress miR-146a expression used recently described mice with targeted deletion of the miR-146a gene 
(Figure S2G). miR-146a
-/-mice contained both monocyte subsets thus Ly-6C hi / Ly-6C lo monocyte conversion should not require miR-146a. Also, miR-146a knockdown did neither alter the ratio ( Figure 2E ) nor the phenotype (Figure S2H ) of monocyte subsets in 8-week-old mice. To compare miR-146a -/-and wild-type monocyte responses as they developed in the same environments, we reconstituted wild-type (CD45.1) mice with equal numbers of miR-146a -/-(CD45.2) and wild-type (EGFP + CD45.2) cells ( Figure S2I ). The absence of miR-146a strongly amplified TNFa-producing Ly-6C hi peritoneal monocytes in response to LPS challenge ( Figures 2F and 2G ). Ly-6C hi monocytes mediate immune defense in early phase of Lm infection (Shi and Pamer, 2011) . Accordingly, Lm-infected miR-146a -/-mice contained reduced numbers of viable Lm 24 hr postinfection when compared to Lm-infected wild-type mice ( Figure 2H ). Amplification of the Ly-6C hi monocyte response in absence of miR-146a was confirmed in a model of sterile peritonitis induced by thioglycollate ( Figure 2I ). Figure 2L ); in marked contrast, miR-146a À/À neutrophils-that do not upregulate miR-146a in vivo-mounted a response that was similar to their wild-type counterparts ( Figure 2K ). Thus miR-146a should regulate Ly-6C hi monocytes at least in part in a cell-intrinsic manner.
Mir-146a Controls Ly-6C hi Monocyte Proliferation and Trafficking in Inflammatory Conditions
In contrast to previous descriptions for other cell types (Nahid et al., 2009; Boldin et al., 2011) , including macrophages (Figure S3A ), the absence of miR-146a did not detectably alter inflammatory cytokine production by Ly-6C hi and Ly-6C lo monocytes on a per-cell basis ( Figures 3A and 3B ). However, LPS challenge increased the percentage of miR-146a -/-Ly-6C hi monocytes undergoing cell division in bone marrow ( Figures 3C and 3D ) and to a lower extent in the spleen and peritoneal cavity (Figure 3D) . The absence of miR-146a did not affect proliferation of Ly-6C lo monocytes ( Figure S3B ). Cocultures of miR-146a -/-and wild-type cells also indicated a proliferative advantage for bone marrow miR-146a -/-Ly-6C hi monocytes ( Figures S3C and S3D ).
In addition, coinjection of bone marrow miR-146a
.2) and control (EGFP + CD45.2) Ly-6C hi monocytes into LPS-treated wild-type (CD45.1) mice showed higher accumulation of miR-146a À/À cells at the site of inflammation within only 6 hr ( Figure 3E ). The chemokine CCL2 controls Ly-6C hi monocyte migration to inflamed sites (Shi and Pamer, 2011) . Interestingly, miR-146a À/À blood Ly-6C hi -but not Ly-6C lo -monocytes expressed the cognate receptor CCR2 at higher levels than their wild-type counterparts ( Figures 3F and S3E ) and migrated more efficiently toward a CCL2 gradient in vitro ( Figure 3G ). These observations indicate that miR-146a controls the expansion of Ly-6C hi monocytes during acute inflammatory conditions in part through elevated proliferation of Ly-6C hi monocytes-predominantly in the bone marrow-and increased trafficking to inflamed sites.
Relb Is a Mir-146a Target We aimed to find endogenous miR-146a target genes that contribute to altering the monocyte response. The screening approach, which compared the expression profiles of miR-146a-predicted target genes in Ly-6C
hi and Ly-6C lo monocytes either at 2 hr or 8 hr after Lm challenge ( Figure S4A and Supplemental Information), identified the transcription factor Relb ( Figure 4A ). Experimental evidence also indicates that Relb is a miR-146a
target. First, ectopic miR-146a expression in resting Ly-6C hi monocytes in vivo reduced Relb transcript levels ( Figure 4B ). Second, NIH 3T3 cells transfected with a luciferase reporter lo monocyte ratios in blood of wild-type (1.03 ± 0.03) and miR-146a -/-(1.05 ± 0.04) mice in steady-state (mean ± SEM).
(F) Fold increase of Ly-6C hi and Ly-6C lo miR-146a -/-monocytes in peritoneal cavity compared to their wild-type counterparts in bone marrow chimeras 4 days after peritoneal LPS injection (n = 4 from two independent experiments).
(G) Number of TNFa-producing wild-type or miR-146a -/-monocytes (same mice as in F).
(H) Colony forming unit (CFU) assay to quantify viable Lm from the spleen of wild-type (n = 6) and miR-146a -/-(n = 5) mice 24 hr after infection. 
experiments). (K) Fold increase of miR-146a
-/-neutrophils and monocytes (GMP donor-derived) compared to their wild-type counterparts in the peritoneal cavity 4 days after LPS challenge (n = 4 from two independent experiments).
(L) Ly-6C expression by donor GMP-derived monocytes (same mice as in K). Data are presented as mean ± SEM (*p < 0.05, **p < 0.01, ***p < 0.001, Student's t test). See also Figure S2 . plasmid expressing Relb 3 0 UTR (ENSMUST00000049912) containing a potential miR-146a binding sequence showed reduced luciferase activity upon miR-146a overexpression. The phenotype was rescued by mutating the seed sequence ( Figure 4C ). Third, immunofluorescence microscopy with a validated anti-Relb Ab ( Figure S4B ) showed efficient nuclear translocation of Relb protein at 30 min after LPS challenge in both wild-type and miR-146a -/-Ly-6C hi monocytes; however at 6 hr cytoplasmic Relb levels were recovered more prominently in the miR-146a -/-cells ( Figure 4D ). Fourth, flow cytometry analysis confirmed that Relb protein levels remained higher in miR-146a -/-Ly-6C hi monocytes upon LPS challenge ( Figure 4E ).
Modulation of Relb Expression Affects the Ly-6C
hi
Monocyte Response
To investigate whether modulation of Relb affects the monocyte response, we generated both Relb hi EGFP hi CD45.1 HSC (that expressed Relb from a cDNA sequence that could not be regulated by miR-146a) and control Relb norm EGFP hi CD45.2 HSC, which were adoptively transferred at a 1:1 ratio into LPS-treated CD45.1/2 recipient animals ( Figure S4C ). Relb overexpression did not alter HSC expansion ( Figure S4D ) but amplified the monocyte response in vivo ( Figure 4F ) and thus recapitulated the phenotype observed for miR-146a -/-Ly-6C hi monocytes. We also injected LPS-treated CD45.1 mice either with miR-146a -/-shRelb EGFP hi HSC (that expressed a miR30-hairpin based shRNA to silence Relb to the levels found in challenged wild-type monocytes) or with miR-146a -/-EGFP hi HSC
(that expressed a control EGFP vector) ( Figures 4G and S4E) . Relb silencing did not alter HSC expansion ( Figure S4F ) but decreased miR-146a -/-Ly-6C hi monocyte responses in vivo ( Figure 4H ). These data indicate that miR-146a can control Ly-6C hi monocyte fate in response to acute inflammatory challenge via Relb targeting.
miR-146a and Relb Expression in Human Monocytes
The human Relb 3 0 UTR contains a binding site for the alternative processing isoform miR-146a-3p (miR-146a*) instead of the ''canonical'' miR-146a-5p isoform (miR-146a) (transcript ENST00000221452, Figure S4G ). miR-146a, and most notably miR-146a*, were detected at higher levels in human CD16 + (CD14 lo ) monocytes than in their CD14 + (CD16 -) counterparts ex vivo ( Figures 4I, S4H , and S4I), and were selectively induced in CD14 + (CD16 -) monocytes 6 hr post-LPS challenge ( Figures  4J, S4J, and S4K) . miR-146a* was also detected in mouse (Cros et al., 2010) . Furthermore, human CD14 + monocytes challenged with LPS decreased Relb mRNA levels ( Figure 4K ), although treatment with a LNA to suppress miR146a* induction ( Figure S4M ) was sufficient to prevent Relb downregulation ( Figures 4K and 4L) .
DISCUSSION
This study provides functional evidence that miR-146a and Relb differentially regulate monocyte subsets. Following inflammatory challenge, modulation of miR-146a expression tunes the amplitude of the Ly-6C hi -but not the Ly-6C lo -monocyte response: premature miR-146a induction aborts Ly-6C hi cell amplification whereas lack of miR-146a induction leads to expansion and increased recruitment of these cells. miR-146a in monocytes targets Relb, which expression levels tune the amplitude of Ly-6C hi monocyte responses.
Recent work has identified miR-146a as a negative regulator of the canonical NF-kB inflammatory cascade by targeting Traf6 and Irak1/2 (O'Connell et al., 2010) and as a tumor suppressor gene by decreasing transcription of NF-kB-targeted genes Zhao et al., 2011) . The present study extends the role of miR-146a to the control of Relb, which is mostly implicated in the noncanonical NF-kB pathway (Vallabhapurapu and Karin, 2009) . Relb has sizable effects on mononuclear phagocytes as it controls dendritic cell development in humans (Platzer et al., 2004) and mice (Burkly et al., 1995; Cejas et al., 2005; Wu et al., 1998) , and the generation of monocyte-derived osteoclasts (Vaira et al., 2008) . In accordance with the present study, the noncanonical NF-kB pathway activator CD40L also controls Ly-6C hi monocyte expansion (Lutgens et al., 2010) . Of note, miR-146a can regulate proinflammatory gene expression by controlling RelB-dependent reversible chromatin remodeling (El Gazzar et al., 2011) .
Ly-6C lo monocytes constitutively express miR-146a in accordance with their noninflammatory properties (Nahrendorf et al., 2007; Auffray et al., 2009 Previous work has identified that miR-146a -/-macrophages produce higher levels of inflammatory cytokines than their wild-type counterparts 
EXPERIMENTAL PROCEDURES Mouse and Human Samples
The studies used 6-to 12-week-old mice. The institutional subcommittee on research animal care at Massachusetts General Hospital approved the animal studies. Human blood was obtained from healthy volunteers and collected in heparinized collection tubes in accordance to a protocol approved by the Committee on microbiological safety at Harvard Medical School.
Monoclonal Antibodies, Flow Cytometry, and Cell Sorting Cell staining and cell sorting was performed as described in Supplemental Experimental Procedures.
Gene Expression Arrays and analysis
Gene expression studies were performed in accordance to MIAME guidelines and are described in Supplemental Experimental Procedures.
In Vivo Challenges LPS from Escherichia coli (serotype O55:B5, Sigma) was given at 0.4 mg/kg in PBS daily i.p. for 4 days (or 7 days when indicated). Lm bacteria (strain EGDe, ATCC) were expanded in Brain Heart Broth (Fluka) and given intravenously at 3 3 10 3 colony forming units. Thioglycollate was given i.p. as a 4% solution in 1 ml RMPI.
In Vitro Challenges
Isolated cells (5-6 3 10 4 ) were plated in complete medium (RPMI, Cellgro Mediatech), 10% FCS (Stem Cell Technologies), 100 U/ml Pen/strep, and 2 mM L-Glu (both Cellgro Mediatech) in round bottom 96-well plates. Stimulations included LPS (100 ng/ml, Sigma), rmTNFa (50 ng/ml, Peprotech), and HKLM (5 3 10 8 heat-killed Lm/ml, Invivo Gen). Luminex cytokine assays (R&D Biosciences) were analyzed on a Luminex FlexMap 3D (Agilent) instrument.
Statistical Analysis
Results were analyzed with Prism 4.0 (GraphPad). P-values were determined using Student's t tests. A p value < 0.05 was taken as statistically significant and higher significance is indicated in the figure legends. All graphs show mean ± SEM.
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The microarray data generated in this study have been deposited to the Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/gds) under accession number GSE32392. 
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